Skin Cancer Evaluation. Simplified.

An objective, non-invasive device to assist GPs in evaluating skin cancer at the point of care.


Skin Evaluation. Simplified.

A handheld, objective device to assist primary care providers in evaluating skin lesions for the risk of cancer in seconds.


Clinical Workflow

1. Assess

Assess the patient's lesions to identify those visually suggestive of skin cancer for which an objective risk assessment would be helpful.

2. Analyze

Use DermaSensor to analyze those lesions of concern to receive a Higher Risk or Lower Risk result for each lesion.

3. Act

Counsel your patient on next steps, such as further investigating the lesion through a biopsy or specialist referral with a Higher Risk result, or reliably ruling out an unnecessary referral or biopsy with a Lower Risk result.

DermaSensor Scan


  • Non-invasive spectroscopy
  • Backed by Science, Powered by Data
  • Provides an objective, non-visual assessment
  • Non-Invasive, Sub-Millimeter Analysis
  • 13% improvement in GPs' skin cancer detection1

1Data on file. DermaSensor use increased physicians’ cancer detection sensitivity from 81% to 94%, and this improvement was statistically significant (p = .0009). There was no statistically significant change in the GP’s specificity, or false positive rate, for benign lesions (p = .3558).

DermaSensor’s technology holds the promise of improving early detection of skin cancer by equipping primary care providers with a tool to better assess it.

David Leffell, M.D.

Chief, Section of Dermatologic Surgery
and Cutaneous Oncology, Yale School of Medicine
Scientific Advisory Board, DermaSensor

With improved performance and confidence in conducting skin cancer checks, you have the potential to significantly grow practice revenues. Speak to one of DermaSensor’s consultants to receive your fully customised FREE Practice Economics Report today.

Get Your Report

Device Animation

DermaSensor looks beyond the visual to improve your decision-making and confidence.

According to the results of a study with 57 GPs, skin cancer detection increases by 13% (from 81% to 94% sensitivity) when using DermaSensor, with no significant decrease in specificity.

Buy Now

Scroll to Top